GOSS - Gossamer Bio, Inc.

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
+0.0800 (+6.35%)
收市:04:00PM EDT
1.3700 +0.03 (+2.24%)
收市後: 06:30PM EDT
買盤0.0000 x 4000
賣出價0.0000 x 2200
今日波幅1.2200 - 1.3750
52 週波幅0.9100 - 15.1950
Beta 值 (5 年,每月)1.20
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.3800
業績公佈日2023年8月07日 - 2023年8月11日
遠期股息及收益率無 (無)
1 年預測目標價6.45
  • Benzinga

    Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success

    Raymond James has downgraded Gossamer Bio Inc (NASDAQ: GOSS) to Market Perform from Outperform following the publication of sotatercept's Phase 3 data in NEJM. The analyst has already thought that seralutinib would exhibit weaker efficacy than Merck & Co Inc's (NYSE: MRK) sotatercept in comparable populations. Using Hodges-Lehman location shift (HLLS) statistic for 6MWD, Merck reported a difference of 40.8m in Phase 3 compared to LSMD of 24.9m in Phase 2, which makes the development path for ser

  • Insider Monkey

    15 Most Shorted Stocks Right Now on Wall Street

    In this article, we will look at the 15 most shorted stocks on Wall Street right now. If you want to explore similar stocks, you can also take a look at 5 Most Shorted Stocks Right Now on Wall Street. Short selling is a way for traders to make money by betting that the price […]

  • InvestorPlace

    7 Top Short-Squeeze Candidates to Watch in February

    While everyone knows that in order to have a market, there must be bulls and bears, that’s not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position. At some point, though, those borrowed shares must be returned. For the bears, they can be returned either at a profit or a loss. Now, in order to panic the bears into buying back their borrowed shares befor

  • Benzinga

    Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis

    BTIG upgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate's benefit, Gossamer Bio Inc's (NASDAQ: GOSS) TORREY Phase 2 results validated dry powder inhaled (DPI)-administered TKIs in pulmonary arterial hypertension (PAH) as a safe and technically viable approach. But Gossamer's DPI seralutinib does not look like a competitive disease-modifying therapy in PAH, with a PVR reduction of only 14% in the overall study popu

  • Benzinga

    Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation

    Gossamer Bio Inc (NASDAQ: GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH). A mean difference in pulmonary vascular resistance (PVR) between the placebo and seralutinib arms of -96.1 dynes, equating to a placebo-corrected improvement of 14.3%, was observed in the study. An observed mean difference in six-minute walk distance (6MWD) between placebo and seralutinib of 6.5 meters numerically favored the seralutinib ar

  • Benzinga

    Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial

    Raymond James maintains Outperform on Gossamer Bio Inc (NASDAQ: GOSS) with a price target down from $18 to $15. The analyst expects a somewhat smaller effect size for seralutinib vs. sotatercept's. Seralutinib Phase 2 TORREY study is on track for topline readout in the second half of November or the first half of December. Merck & Co Inc (NYSE: MRK) is developing sotatercept as an add-on to stable background therapy for pulmonary arterial hypertension (PAH). Merck recently reported topline data